Gregory S Cooper1,2, Tzuyung Doug Kou1. 1. University Hospitals Cleveland Medical Center, Division of Gastroenterology, Cleveland, Ohio. 2. Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio.
Abstract
BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is frequently used to promote new bone growth after lumbar fusion surgery. However, because BMP receptors are found on cancer cells, there is concern about potential cancer following treatment with rhBMP-2. Data from clinical trials have reported divergent results and have been limited by small sample sizes and relatively short follow-up. We therefore examined the long-term risk of cancer following treatment with rhBMP-2 after lumbar fusion surgery. METHODS: Using the MarketScan Commercial Claims and Encounters database, we identified all patients <65 years without prior cancer who underwent lumbar fusion surgery between October 2003 and December 2009 and were followed at least 3 years after surgery. Development of any Surveillance Epidemiology and End Results malignancy in follow-up was identified through diagnosis and procedure codes. RESULTS: Among 39 448 eligible patients, 2345 (5.9%) received rhBMP at surgery; the median follow-up in this population was 4.87 years. Cancer in follow-up was observed in 49 BMP-treated patients (0.43/100 person years) and 1072 nontreated patients (0.58/100 person years). Use of rhBMP was associated with a cancer risk similar to that of untreated patients in both univariate (hazard ratio, 0.80; 95%, CI 0.54-1.19) and multivariate proportional hazards analyses (hazard ratio, 0.81; 95% CI, 0.54-1.20). Similar findings were observed in a secondary analysis after adjustment for likelihood of rhBMP administration. CONCLUSIONS: In this retrospective cohort with at least 3 years of follow-up, administration of rhBMP during lumbar fusion surgery was not associated with an increased risk of subsequent cancer. LEVEL OF EVIDENCE: 4.
BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is frequently used to promote new bone growth after lumbar fusion surgery. However, because BMP receptors are found on cancer cells, there is concern about potential cancer following treatment with rhBMP-2. Data from clinical trials have reported divergent results and have been limited by small sample sizes and relatively short follow-up. We therefore examined the long-term risk of cancer following treatment with rhBMP-2 after lumbar fusion surgery. METHODS: Using the MarketScan Commercial Claims and Encounters database, we identified all patients <65 years without prior cancer who underwent lumbar fusion surgery between October 2003 and December 2009 and were followed at least 3 years after surgery. Development of any Surveillance Epidemiology and End Results malignancy in follow-up was identified through diagnosis and procedure codes. RESULTS: Among 39 448 eligible patients, 2345 (5.9%) received rhBMP at surgery; the median follow-up in this population was 4.87 years. Cancer in follow-up was observed in 49 BMP-treated patients (0.43/100 person years) and 1072 nontreated patients (0.58/100 person years). Use of rhBMP was associated with a cancer risk similar to that of untreated patients in both univariate (hazard ratio, 0.80; 95%, CI 0.54-1.19) and multivariate proportional hazards analyses (hazard ratio, 0.81; 95% CI, 0.54-1.20). Similar findings were observed in a secondary analysis after adjustment for likelihood of rhBMP administration. CONCLUSIONS: In this retrospective cohort with at least 3 years of follow-up, administration of rhBMP during lumbar fusion surgery was not associated with an increased risk of subsequent cancer. LEVEL OF EVIDENCE: 4.
Authors: Eugene J Carragee; Gilbert Chu; Rajat Rohatgi; Eric L Hurwitz; Bradley K Weiner; S Tim Yoon; Garet Comer; Branko Kopjar Journal: J Bone Joint Surg Am Date: 2013-09-04 Impact factor: 5.284
Authors: Daniel C Beachler; Elizabeth L Yanik; Brook I Martin; Ruth M Pfeiffer; Sohail K Mirza; Richard A Deyo; Eric A Engels Journal: J Bone Joint Surg Am Date: 2016-07-06 Impact factor: 5.284
Authors: Magdalena Bieniasz; Katarzyna Oszajca; Mak Eusebio; Jacek Kordiak; Jacek Bartkowiak; Janusz Szemraj Journal: Lung Cancer Date: 2009-03-25 Impact factor: 5.705
Authors: Jayesh P Thawani; Anthony C Wang; Khoi D Than; Chia-Ying Lin; Frank La Marca; Paul Park Journal: Neurosurgery Date: 2010-02 Impact factor: 4.654
Authors: H Soda; E Raymond; S Sharma; R Lawrence; C Cerna; L Gomez; G A Timony; D D Von Hoff; E Izbicka Journal: Anticancer Drugs Date: 1998-04 Impact factor: 2.248